| Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome Y Allory, W Beukers, A Sagrera, M Flández, M Marqués, M Márquez, ... European urology 65 (2), 360-366, 2014 | 300 | 2014 |
| Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non–muscle-invasive bladder cancer BWG Van Rhijn, TCM Zuiverloon, AN Vis, F Radvanyi, ... European urology 58 (3), 433-441, 2010 | 231 | 2010 |
| Functional characterization of the lectin pathway of complement in human serum A Roos, LH Bouwman, J Munoz, T Zuiverloon, MC Faber-Krol, ... Molecular immunology 39 (11), 655-668, 2003 | 214 | 2003 |
| Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review TCM Zuiverloon, AJM Nieuweboer, H Vékony, WJ Kirkels, CH Bangma, ... European urology 61 (1), 128-145, 2012 | 199 | 2012 |
| Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle–Invasive Bladder Cancer TCM Zuiverloon, MNM van der Aa, TH van der Kwast, EW Steyerberg, ... Clinical Cancer Research 16 (11), 3011-3018, 2010 | 134 | 2010 |
| A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene CD Hurst, TCM Zuiverloon, C Hafner, EC Zwarthoff, MA Knowles BMC research notes 2, 1-6, 2009 | 118 | 2009 |
| Antibody‐mediated activation of the classical pathway of complement may compensate for mannose‐binding lectin deficiency A Roos, P Garred, ME Wildenberg, NJ Lynch, JR Munoz, TCM Zuiverloon, ... European journal of immunology 34 (9), 2589-2598, 2004 | 102 | 2004 |
| Targeted therapies in bladder cancer: an overview of in vivo research KEM Van Kessel, TCM Zuiverloon, AR Alberts, JL Boormans, ... Nature reviews Urology 12 (12), 681-694, 2015 | 90 | 2015 |
| Systematic review: characteristics and preclinical uses of bladder cancer cell lines T Zuiverloon, FC De Jong, JC Costello, D Theodorescu Bladder cancer 4 (2), 169-183, 2018 | 84 | 2018 |
| A methylation assay for the detection of non‐muscle‐invasive bladder cancer (NMIBC) recurrences in voided urine TCM Zuiverloon, W Beukers, KA van der Keur, JR Munoz, CH Bangma, ... BJU international 109 (6), 941-948, 2012 | 82 | 2012 |
| A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus MA Seelen, EA van der Bijl, LA Trouw, TCM Zuiverloon, JR Munoz, ... Rheumatology 44 (1), 111-119, 2005 | 82 | 2005 |
| Prognostic value of molecular markers, sub‐stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer BWG Van Rhijn, L Liu, AN Vis, PJ Bostrom, TCM Zuiverloon, NE Fleshner, ... BJU international 110 (8), 1169-1176, 2012 | 77 | 2012 |
| FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment? BWG van Rhijn, LS Mertens, R Mayr, PJ Bostrom, FX Real, EC Zwarthoff, ... European Urology 78 (5), 682-687, 2020 | 72 | 2020 |
| Optimization of Nonmuscle Invasive Bladder Cancer Recurrence Detection Using a Urine Based FGFR3 Mutation Assay TCM Zuiverloon, SS Tjin, M Busstra, CH Bangma, ER Boevé, ... The Journal of urology 186 (2), 707-712, 2011 | 56 | 2011 |
| Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications BWG Van Rhijn, M Musquera, L Liu, AN Vis, TCM Zuiverloon, ... Modern Pathology 28 (5), 695-705, 2015 | 55 | 2015 |
| Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project TCM Zuiverloon, W Beukers, KA van der Keur, AJM Nieuweboer, ... The Journal of urology 189 (5), 1945-1951, 2013 | 55 | 2013 |
| PD-L1 Antibody Comparison in Urothelial Carcinoma. M Rijnders, AAM van der Veldt, TCM Zuiverloon, K Grünberg, ... European Urology 75 (3), 538-540, 2018 | 47 | 2018 |
| FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies KEM van Kessel, LC Kompier, EW de Bekker-Grob, TCM Zuiverloon, ... The Journal of urology 189 (5), 1676-1681, 2013 | 45 | 2013 |
| Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR L Dyrskjøt, T Reinert, A Novoradovsky, TCM Zuiverloon, W Beukers, ... British journal of cancer 107 (8), 1392-1398, 2012 | 45 | 2012 |
| Microhematuria assessment an IBCN consensus—Based upon a critical review of current guidelines BJ Schmitz-Dräger, EC Kuckuck, TCM Zuiverloon, EC Zwarthoff, ... Urologic Oncology: Seminars and Original Investigations 34 (10), 437-451, 2016 | 39 | 2016 |
Ellen Zwarthoffhoogleraar moleculaire pathologie, Erasmus MC RotterdamVerified email at erasmusmc.nl
